K13 Propeller Marker Detection for Artemisinin Resistance

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The emergence of Plasmodium falciparum resistance to artemisinin derivatives threatens global malaria control efforts due to the lack of reliable molecular markers for detecting and containing resistant parasites, hindering rapid detection and monitoring of resistance spread.

Innovation Solution

A method and kit for detecting mutated K-13 propeller nucleic acids or proteins in Plasmodium falciparum samples using PCR and sequencing, allowing for the identification of wild-type or mutant alleles associated with artemisinin resistance, enabling effective surveillance and treatment adjustments.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If clinical ART resistance monitoring is performed using traditional methods (parasite clearance half-life measurement), then resistance detection is possible, but the process is expensive, labor-intensive, and time-consuming

Engineering Contradiction:

Improveresistance detection accuracyVSAvoiddetection speed

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent replaces complex clinical monitoring methods (parasite clearance half-life measurement requiring multiple blood draws and microscopy) with a molecular biology-based PCR detection system. This substitution enables resistance detection through genetic marker identification rather than phenotypic observation, dramatically reducing time and labor requirements while maintaining detection accuracy.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The invention creates a molecular copy (DNA sequence) of the resistance phenotype by identifying and amplifying specific genetic markers associated with artemisinin resistance. Instead of monitoring the actual parasite response to drugs over time, the system detects resistance through copying and analyzing the genetic blueprint that predicts resistance, enabling rapid assessment without waiting for clinical outcomes.

Inventive Principle:

Principle #26Copying

2Loss of information

If molecular marker development is pursued through genome-wide association studies, then comprehensive genetic analysis is achieved, but uncertainties about parasite population structure confound the results

Engineering Contradiction:

Improvegenetic analysis completenessVSAvoidmarker identification accuracy

Core Design Contradiction:

Loss of informationVSReliability

Solution Approach 1:

The patent extracts specific, pre-identified genetic markers from the complex genome-wide data set. Rather than attempting to analyze all genetic variations simultaneously (which is confounded by population structure), the invention isolates and focuses on particular molecular markers in the K-13 propeller domain that have been shown to correlate with resistance, thereby eliminating the confounding effects of population structure while retaining the ability to detect resistance.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention applies local quality by focusing analysis on specific regions of the genome (K-13 propeller domain mutations) rather than treating the entire genome uniformly. This localized approach to marker identification allows for reliable resistance detection in specific genetic contexts without being overwhelmed by the complexity of global population structure variations.

Inventive Principle:

Principle #3Local quality

3Area of stationary object

If widespread molecular surveillance is implemented without a validated molecular marker, then monitoring coverage is limited, but the lack of a molecular marker hampers containment efforts and hinders rapid detection

Engineering Contradiction:

Improvemonitoring coverageVSAvoidresistance detection capability

Core Design Contradiction:

Area of stationary objectVSReliability

Solution Approach 1:

The patent performs preliminary validation of molecular markers through laboratory adaptation studies and correlation with clinical resistance phenotypes before deploying the markers for widespread surveillance. By pre-validating the K-13 propeller domain markers and establishing their association with resistance in controlled settings, the invention enables reliable large-scale monitoring to be implemented immediately without requiring validation at each surveillance site.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach provides a molecular marker for tracking artemisinin-resistant parasites, facilitating containment and treatment optimization, thereby supporting malaria control and elimination efforts by accurately identifying resistant strains and guiding treatment protocols.

Implementation Method 1

detecting the presence of a mutated K-13 propeller nucleic acid or protein in the sample

Methodology Applied

Scientific EffectPolymerase Chain Reaction (PCR):

Implementation Method 2

The presence of a mutated K-13 propeller nucleic acid in the sample is detected by sequencing

Methodology Applied

Scientific EffectDNA Sequencing:

Data Source

PatentUS11732312B2Molecular marker of plasmodium falciparum artemisinin resistance

Publication Date: 2023.08.22 INST PASTEUR

AI summary

K13-propeller polymorphism is a useful molecular marker for tracking the emergence and spread of ART-resistant P. falciparum. The invention encompasses methods, compositions, and kits for detecting and genotyping Plasmodium, for example, Plasmodium falciparum. The methods, compositions, and kits can be used to detect the presence or absence of a mutated K-13 propeller nucleic acid or protein in the sample.